Rho-kinase inhibitors

US6943172B2 · kind B2 · utility

Assignee

• Bayer Pharmaceuticals Corporation · US

Inventors

• Dhanapalan Nagarathnam · Bethany, US
• Jacques Dumas · Neuilly-Plaisance, FR
• Holia Hatoum-Mokdad · Hamden, US
• Stephen Boyer · Fairfield, US
• Hans Pluempe · Wuppertal, DE

Key dates

• Filing date: Jan 23, 2003
• Grant date: Sep 13, 2005
• Expiry date: Mar 2, 2023

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D401/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are compounds and derivatives thereof, their synthesis, and their use as Rho-kinase inhibitors. These compounds are useful for inhibiting tumor growth, treating erectile dysfunction, and treating other indications mediated by Rho-kinase, e.g., coronary heart disease.